[
    [
        {
            "time": "2018-11-05",
            "original_text": "Top Research Reports for Novo Nordisk, TJX Companies & Cigna",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "TJX Companies",
                    "Cigna"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "retail",
                    "insurance"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Top Research Reports for Novo Nordisk, TJX Companies & Cigna",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-03",
            "original_text": "Why 2018 Could Be An 'Explosive' Year For Biotech Mergers",
            "features": {
                "keywords": [
                    "Biotech",
                    "Mergers",
                    "Explosive"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Why 2018 Could Be An 'Explosive' Year For Biotech Mergers",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 4,
                "Headline_Structure": 9,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-01-04",
            "original_text": "Stocks To Watch: Bristol-Myers Squibb Sees RS Rating Jump To 83",
            "features": {
                "keywords": [
                    "Bristol-Myers Squibb",
                    "RS Rating",
                    "Jump"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Stocks To Watch: Bristol-Myers Squibb Sees RS Rating Jump To 83",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]